Pharmacology & human phase 1 safety & dose escalation studies using anti-GP88 in aggressive breast cancer
Ended Project Grant Awarded Last action
- Award ID
- R44CA224718
- Recipient
-
A&G Pharmaceutical, Inc. UEI SN6SWFABJXL1
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,875,358
Award facts
- Assistance listing
- 93.395 Cancer Treatment Research
- Completion date
- Originally
- Place of performance
- Maryland, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $826,939 | |
| Amendment | $826,939 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $1,062,115 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Original award | $159,365 |
Show all 18
Quick answers
Who received award R44CA224718?
R44CA224718 was awarded to A&G Pharmaceutical, Inc. by National Cancer Institute (National Institutes of Health) on September 1, 2018.
How much is award R44CA224718 worth?
$2,875,358 has been obligated on R44CA224718.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award